Innate Pharma S.A. (IPHYF)
IPHYF Stock Price Chart
Explore Innate Pharma S.A. interactive price chart. Choose custom timeframes to analyze IPHYF price movements and trends.
IPHYF Company Profile
Discover essential business fundamentals and corporate details for Innate Pharma S.A. (IPHYF) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
9 Jun 2015
Employees
181.00
Website
https://www.innate-pharma.comCEO
Jonathan E. Dickinson
Description
Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), a monoclonal antibody blocking C5a binding to C5aR1 that is in Phase II clinicals trials for the treatment of COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; and IPH6101, a NKp46-based NK cell engager for the generation and evaluation of up to two bispecific NK cell engagers. Its products in preclinical trials are IPH43, an anti-MICA/B antibody drug conjugate; Anti-Siglec-9, an antibody program; IPH65, a tetraspecific proprietary antibody; IPH25, a checkpoint inhibitor; and IPH62 and IPH64 programs. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. The company was incorporated in 1999 and is headquartered in Marseille, France.
IPHYF Financial Timeline
Browse a chronological timeline of Innate Pharma S.A. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 17 Sept 2025
Earnings released on 12 May 2025
EPS came in at -$0.32 falling short of the estimated -$0.26 by -19.57%, while revenue for the quarter reached $285.80K , missing expectations by -98.41%.
Earnings released on 13 Nov 2024
EPS came in at -$0.33 falling short of the estimated -$0.30 by -9.78%, while revenue for the quarter reached $13.27M , missing expectations by -0.06%.
Earnings released on 14 May 2024
EPS came in at -$0.13 surpassing the estimated -$0.45 by +71.53%, while revenue for the quarter reached $23.58M , beating expectations by +27.02%.
Earnings released on 14 Sept 2023
EPS came in at $0.02 falling short of the estimated $0.09 by -74.36%, while revenue for the quarter reached $43.85M , missing expectations by -37.06%.
Earnings released on 23 Mar 2023
EPS came in at -$0.87 falling short of the estimated -$0.42 by -107.26%, while revenue for the quarter reached $8.95M , missing expectations by -51.38%.
Earnings released on 14 Nov 2022
EPS came in at $0.08 falling short of the estimated $0.39 by -79.23%, while revenue for the quarter reached $43.17M , missing expectations by -49.83%.
Earnings released on 10 May 2022
EPS came in at -$0.41 falling short of the estimated -$0.19 by -121.07%, while revenue for the quarter reached $3.17M , missing expectations by -87.90%.
Earnings released on 26 Oct 2021
EPS came in at -$0.36 falling short of the estimated -$0.30 by -17.80%, while revenue for the quarter reached $11.06M , missing expectations by -63.78%.
Earnings released on 11 May 2021
EPS came in at -$0.83 falling short of the estimated -$0.09 by -828.83%, while revenue for the quarter reached $33.10M , missing expectations by -52.48%.
Earnings released on 17 Nov 2020
EPS came in at -$0.15 falling short of the estimated -$0.08 by -84.24%, while revenue for the quarter reached $33.58M , missing expectations by -18.47%.
IPHYF Stock Performance
Access detailed IPHYF performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.